FHTXFoghorn Therapeutics Inc.

FHTX Stock Price, Valuation & Chart | Foghorn Therapeutics Inc.

Compare

$5.170-0.52 (-9.14%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology FHTX intrinsic value FHTX calculated fair value vs price

Overview Financials Dividends Ratios

FHTX Historical price chart

FHTX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization303.55M

PE Ratio-5.28

EPS-0.98

Trading Volume948.81K

Today's High/Low5.89/5.03

Dividend Yield0.00

52 Week High/Low7.61/3.27

Shares Outstanding58.71M

FHTX Financial Statement

FHTX Analyst ratings

FHTX Analysis & performance metrics

FHTX Company profile

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin…

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the…

FHTX Management team

Name

Position

Gerald R. Crabtree M.d.

Founder & Member of Scientific Advisory Board

Kristian Humer M.B.A.CFO

Chief Financial Officer

Michael J. LaCascia J.D.

Chief Legal Officer

Steven F. Bellon Ph.D.

Chief Scientific Officer

Adrian H. B. GottschalkCEO

President, Chief Executive Officer & Director

Karin HellsvikCEO

Chief of Staff to the Chief Executive Officer, Vice President of Corporate Affairs & Investor Relations

Carlos Costa

Chief People Officer

Alfonso Quintas Cardama M.D.

Chief Medical Officer

Name

Position

Gerald R. Crabtree M.d.

Founder & Member of Scientific Advisory Board

Kristian Humer M.B.A.CFO

Chief Financial Officer

Michael J. LaCascia J.D.

Chief Legal Officer

Steven F. Bellon Ph.D.

Chief Scientific Officer

Adrian H. B. GottschalkCEO

President, Chief Executive Officer & Director

Karin HellsvikCEO

Chief of Staff to the Chief Executive Officer, Vice President of Corporate Affairs & Investor Relations

Carlos Costa

Chief People Officer

Alfonso Quintas Cardama M.D.

Chief Medical Officer

Management Team

Gerald R. Crabtree M.d.

Founder & Member of Scientific Advisory Board

Kristian Humer M.B.A.CFO

Chief Financial Officer

Michael J. LaCascia J.D.

Chief Legal Officer

Steven F. Bellon Ph.D.

Chief Scientific Officer

Adrian H. B. GottschalkCEO

President, Chief Executive Officer & Director

Karin HellsvikCEO

Chief of Staff to the Chief Executive Officer, Vice President of Corporate Affairs & Investor Relations

Carlos Costa

Chief People Officer

Alfonso Quintas Cardama M.D.

Chief Medical Officer

Management

Gerald R. Crabtree M.d.

Founder & Member of Scientific Advisory Board

Kristian Humer M.B.A.CFO

Chief Financial Officer

Michael J. LaCascia J.D.

Chief Legal Officer

Steven F. Bellon Ph.D.

Chief Scientific Officer

Adrian H. B. GottschalkCEO

President, Chief Executive Officer & Director

Karin HellsvikCEO

Chief of Staff to the Chief Executive Officer, Vice President of Corporate Affairs & Investor Relations

Carlos Costa

Chief People Officer

Alfonso Quintas Cardama M.D.

Chief Medical Officer

Total 8 executives

FHTX Frequently asked questions

What is Foghorn Therapeutics Inc. (FHTX) Stock Price?

Current stock price of Foghorn Therapeutics Inc. (FHTX) stock is $5.170. The stock price is -9.14% lower in the session. The intraday range can be seen from this page. Volume of Foghorn Therapeutics Inc. (FHTX) stock is 948.81K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Foghorn Therapeutics Inc. (FHTX) stock price going up or down today?

The stock price of Foghorn Therapeutics Inc. (FHTX) can change with earnings, company news, and overall market sentiment. Foghorn Therapeutics Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Foghorn Therapeutics Inc. stock expensive at its current price?

Whether Foghorn Therapeutics Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for FHTX on this page is -5.28. EPS on this page is -0.98. Compare those figures with peers and growth expectations before deciding if the current Foghorn Therapeutics Inc. price is justified.

How has the stock price of Foghorn Therapeutics Inc. (FHTX) performed historically?

Historical performance for Foghorn Therapeutics Inc. (FHTX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how FHTX reacted to past earnings and market events.

Should I buy Foghorn Therapeutics Inc. (FHTX) stock, at this price?

Buying Foghorn Therapeutics Inc. (FHTX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.